Derivation of embryonic stem cells

Patent metadata

Field	Value
Publication number	US-9550974-B2
Application number	US-201414154163-A
Country	US
Kind code	B2
Filing date	Jan 13, 2014
Priority date	Nov 4, 2004
Publication date	Jan 24, 2017
Grant date	Jan 24, 2017

Abstract

This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.

First claim

We claim:

1. A method of producing a differentiated cell or tissue from a mammalian ES cell, the method comprising:
(a) culturing at least one isolated blastomere obtained from a mammalian embryo until a clump containing blastomere progeny cells forms;
(b) culturing the blastomere progeny cells for a suitable amount of time to obtain ES cells derived from the at least one isolated blastomere; and
(c) differentiating the ES cells into desired differentiated cells or tissues,
wherein the least one isolated blastomere of (a) and/or blastomere progeny cells of (a) and (b) are cultured in a medium comprising factors that inhibit differentiation.

2. The method of claim 1 , further comprising: (d) isolating the differentiated cells or tissues.

3. The method of claim 1 , wherein the differentiated cells or tissues are mesodermal, ectodermal, or endodermal cells or tissues.

4. The method of claim 2 , wherein the differentiated cells or tissues are mesodermal, ectodermal, or endodermal cells or tissues.

5. The method of claim 1 , wherein the differentiated cells or tissues are retinal pigment epithelial cells.

6. The method of claim 1 , wherein the differentiated cells or tissues are suitable for transplantation into a subject.

7. The method of claim 5 , wherein the differentiated cells or tissues are suitable for transplantation into a subject.

8. The method of claim 5 , wherein the retinal pigment epithelial cells are suitable for treatment of macular degeneration.

Assignees

• Advanced Cell Tech Inc
• Astellas Inst For Regenerative Medicine

Inventors

• Lanza Robert P
• Chung Young Gie

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title